The IPO Buzz: ArriVent BioPharma Upsizes IPO & Prices Deal at $18.00 Mid-Point
More stock at the mid-point: That’s how lung cancer biotech ArriVent BioPharma (AVBP) played it when pricing its IPO on Thursday night (Jan 25, 2024). ArriVent BioPharma increased the IPO’s size to 9.72 million shares – up from 8.33 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of […]
January 26, 2024 Read More